FEDERICO
LARA VILLOSLADA
Hospital Universitario Virgen de las Nieves
Granada, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (7)
2015
-
Long-term safety of early consumption of Lactobacillus fermentum CECT5716: A 3-year follow-up of a randomized controlled trial
Pharmacological Research, Vol. 95-96, pp. 12-19
2012
-
Human milk probiotic lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants
Journal of Pediatric Gastroenterology and Nutrition, Vol. 54, Núm. 1, pp. 55-61
-
Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1-6 months of age: A Randomized Controlled Trial
Pharmacological Research, Vol. 65, Núm. 2, pp. 231-238
-
Szczep Lactobacillus fermentum CECT5716 jest bezpieczny i dobrze tolerowany u niemowla̧t w wieku 1-6 miesiȩcy: randomizowane badanie kliniczne z grupa̧ kontrolna̧
Pediatria Polska, Vol. 87, Núm. 6, pp. 656-666
2009
-
A probiotic dairy product containing L. gasseri CECT5714 and L. coryniformis CECT5711 induces immunological changes in children suffering from allergy
Pediatric Allergy and Immunology, Vol. 20, Núm. 6, pp. 592-600
2007
-
A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis
British Journal of Nutrition, Vol. 97, Núm. 1, pp. 96-103
2006
-
Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis
Clinical Nutrition, Vol. 25, Núm. 3, pp. 477-488